药物信息为CLOZAPINE TABLETS, USP (Mylan Pharmaceuticals Inc.): CONTRAINDICATIONS
- DESCRIPTION
- CONTRAINDICATIONS
- DRUG ABUSE AND DEPENDENCE
- HOW SUPPLIED
- Diseases/Conditions Related to CLOZAPINE TABLETS, USP (Mylan Pharmaceuticals Inc.)
- 外部链接相关的CLOZAPINE TABLETS, USP (Mylan Pharmaceuticals Inc.)
Clozapine is contraindicated in patients with a previous hypersensitivity to clozapine or any other component of this drug, in patients with myeloproliferative disorders, uncontrolled epilepsy, paralytic ileus, or a history of clozapine induced agranulocytosis or severe granulocytopenia. As with more typical antipsychotic drugs, clozapine is contraindicated in severe central nervous system depression or comatose states from any cause.
Clozapine should not be used simultaneously with other agents having a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. The mechanism of clozapine induced agranulocytosis is unknown; nonetheless, it is possible that causative factors may interact synergistically to increase the risk and/or severity of bone marrow suppression.
- Drug Information Provided by National Library of Medicine (NLM).
